NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $12.83 -0.23 (-1.76 %) (As of 07/22/2018 05:03 AM ET)Previous Close$12.83Today's Range$12.71 - $13.1352-Week Range$7.67 - $17.29Volume826,633 shsAverage Volume517,257 shsMarket Capitalization$1.38 billionP/E Ratio-10.10Dividend YieldN/ABeta0.44 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas. Receive LXRX News and Ratings via Email Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:LXRX CUSIP52887210 Webwww.lexpharma.com Phone281-863-3000 Debt Debt-to-Equity Ratio8.85 Current Ratio2.72 Quick Ratio2.70 Price-To-Earnings Trailing P/E Ratio-10.10 Forward P/E Ratio-9.65 P/E GrowthN/A Sales & Book Value Annual Sales$90.33 million Price / Sales15.03 Cash FlowN/A Price / CashN/A Book Value$0.49 per share Price / Book26.18 Profitability EPS (Most Recent Fiscal Year)($1.27) Net Income$-129,050,000.00 Net Margins-140.09% Return on Equity-213.32% Return on Assets-36.99% Miscellaneous Employees174 Outstanding Shares105,830,000Market Cap$1,382.16 Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions What is Lexicon Pharmaceuticals' stock symbol? Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX." How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.03. The biopharmaceutical company earned $25.21 million during the quarter, compared to the consensus estimate of $25.30 million. Lexicon Pharmaceuticals had a negative net margin of 140.09% and a negative return on equity of 213.32%. The company's revenue was up 37.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. View Lexicon Pharmaceuticals' Earnings History. When is Lexicon Pharmaceuticals' next earnings date? Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Lexicon Pharmaceuticals. What price target have analysts set for LXRX? 6 equities research analysts have issued 1-year price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $10.00 to $42.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $24.80 in the next year. This suggests a possible upside of 93.3% from the stock's current price. View Analyst Ratings for Lexicon Pharmaceuticals. What is the consensus analysts' recommendation for Lexicon Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Lexicon Pharmaceuticals stock? Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock: 1. Needham & Company LLC analysts commented, "Lexicon presented additional data from sotagliflozin Phase 3 program in at ADA mtg and published full 52wk data from both inTANDEM1 and inTANDEM2 trials. We spoke w/ mgmt for an update. Overall sotagliflozin safety/ efficacy profile is unch and we continue to believe the drug will have a role in T1D treatment. Additional data from dapagliflozin program in T1D were also presented (AstraZeneca/ BMS). Sotagliflozin may have modest benefits as a dual SGLT1/2 inhibitor over single SGLT2 inhibition, but it is still a challenge to compare the drugs across different trials. Maintain HOLD due to slow Xermelo launch and our expectation that Phase 3 T2D next year will help clarify potential overall advantages of sotagliflozin over SGLT2 inhibitors." (6/25/2018) 2. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (5/8/2018) 3. Wedbush analysts commented, "Management announced the initiation of its second global Phase 2/3 clinical trial for Plinabulin (for the prevention of chemotherapy-induced neutropenia CIN). Study 106, initiated in China, is enrolling patients who receive TAC (taxotere, doxorubicin and cyclophosphamide) chemotherapy, which often results in severe neutropenia, to demonstrate Plinabulin’s superiority compared with Neulasta, a G-CSF." (11/30/2017) Who are some of Lexicon Pharmaceuticals' key competitors? Some companies that are related to Lexicon Pharmaceuticals include United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dr.Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL), Array Biopharma (ARRY), OPKO Health (OPK) and Ironwood Pharmaceuticals (IRWD). Who are Lexicon Pharmaceuticals' key executives? Lexicon Pharmaceuticals' management team includes the folowing people: Mr. Lonnel Coats, Pres, CEO & Director (Age 53)Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 53)Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 55)Dr. Praveen Tyle, Exec. VP of R&D (Age 58)Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 59) Has Lexicon Pharmaceuticals been receiving favorable news coverage? Media headlines about LXRX stock have been trending somewhat positive this week, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.42 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Who are Lexicon Pharmaceuticals' major shareholders? Lexicon Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include INVUS, L.P. (55.80%) and Fox Run Management L.L.C. (0.04%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals. Which institutional investors are selling Lexicon Pharmaceuticals stock? LXRX stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. View Insider Buying and Selling for Lexicon Pharmaceuticals. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Lexicon Pharmaceuticals' stock price today? One share of LXRX stock can currently be purchased for approximately $12.83. How big of a company is Lexicon Pharmaceuticals? Lexicon Pharmaceuticals has a market capitalization of $1.38 billion and generates $90.33 million in revenue each year. The biopharmaceutical company earns $-129,050,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Lexicon Pharmaceuticals employs 174 workers across the globe. How can I contact Lexicon Pharmaceuticals? Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000. MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 292 (Vote Outperform)Underperform Votes: 244 (Vote Underperform)Total Votes: 536MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?